Singular Genomics Systems, Inc. (Omic): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage en évolution rapide des technologies génomiques, Sinomb Genomics Systems, Inc. (OMIC) émerge comme un innovateur révolutionnaire, transformant notre façon de comprendre et de tirer parti des informations génétiques. En intégrant de manière transparente les plates-formes de séquençage avancées avec des capacités de recherche de pointe, la société redéfinit la médecine de précision et la découverte scientifique, offrant aux chercheurs et aux cliniciens des informations sans précédent sur le monde complexe de la génomique. Leur modèle commercial complet représente un plan stratégique pour révolutionner l'analyse génétique, promettant de débloquer un potentiel transformateur dans les domaines académique, pharmaceutique et clinique.

Singular Genomics Systems, Inc. (Omic) - Modèle d'entreprise: partenariats clés

Collaboration avec les établissements de recherche universitaires

Depuis 2024, Singular Genomics a établi des partenariats de recherche avec:

Institution	Focus de collaboration spécifique	Année établie
Université de Stanford	Développement de la technologie de séquençage génomique	2022
École de médecine de Harvard	Recherche en génomique du cancer	2023

Partenariats stratégiques avec les sociétés pharmaceutiques

Les partenariats pharmaceutiques actuels comprennent:

• Miserrer & CO.: Collaboration de diagnostic d'oncologie de précision
• Pfizer: projet d'identification des biomarqueurs génomiques
• AstraZeneca: Contrat de recherche en médecine personnalisée

Alliances avec des entreprises de biotechnologie et de diagnostic

PARTENATSES DE BIOTECHNOLOGIE CLÉS:

Entreprise	Valeur de partenariat	Type de collaboration
Illumina	3,5 millions de dollars	Licence de technologie
Roche Diagnostics	2,8 millions de dollars	Intégration de la plate-forme génomique

Organisations de fabrication de contrats

Partners d'assistance manufacturier:

• Groupe Lonza: production d'équipements de séquençage génomique
• Wuxi Apptec: réactif et fabrication de consommables

Capital-risque et sociétés d'investissement

Partenariats de financement à partir de 2024:

Investisseur	Montant d'investissement	Année d'investissement
Capital-avant	45 millions de dollars	2023
Arch Venture Partners	38 millions de dollars	2023

Singular Genomics Systems, Inc. (Omic) - Modèle d'entreprise: activités clés

Développer des plateformes de séquençage génomique avancées

Depuis le Q4 2023, la génomique singulière s'est concentrée sur le développement de la plate-forme de séquençage G4, avec les spécifications techniques suivantes:

Métrique de la plate-forme	Spécification
Déborder	Jusqu'à 1,6 milliard de lectures par course
Temps d'exécution	Moins de 24 heures
Longueur de lecture	Jusqu'à 2x300 paires de bases

Recherche et développement de nouvelles technologies génomiques

Investissement de R&D pour 2023:

• Total des dépenses de R&D: 41,2 millions de dollars
• Personnel R&D: 62 chercheurs à temps plein
• Demandes de brevet: 7 nouveaux brevets technologiques génomiques déposés

Commercialisation de solutions de test génomiques

Zones de concentration commerciale en 2023:

Segment de marché	Client cibler
Oncologie	Institutions de recherche
Dépistage des maladies génétiques	Laboratoires cliniques
Santé reproductive	Cliniques de fertilité

Innovation continue des produits et améliorations technologiques

Mesures d'innovation pour 2023:

• Cycles d'amélioration de la technologie: 3 mises à niveau principales de plate-forme
• Améliorations du logiciel: 12 mises à jour de l'algorithme de calcul
• Intégration d'apprentissage automatique: développé 4 nouveaux outils d'analyse dirigés par l'IA

Validation clinique et scientifique des technologies génomiques

Activités de validation en 2023:

Type de validation	Nombre d'études
Essais cliniques	6 études terminées
Publications évaluées par des pairs	9 publications scientifiques
Collaborations de validation externe	11 partenariats de recherche

Singular Genomics Systems, Inc. (Omic) - Modèle d'entreprise: Ressources clés

Technologie de séquençage génomique propriétaire

Singular Genomics Systems, Inc. a développé la plate-forme de séquençage G4, qui a les spécifications suivantes:

Métrique de la plate-forme	Spécification
Déborder	Jusqu'à 1,2 milliard de lectures par course
Temps d'exécution	16-48 heures
Longueur de lecture	Paies de base 2x150

Infrastructure de calcul haute performance

Les ressources informatiques comprennent:

• Systèmes de traitement des données génomiques basées sur le cloud
• Grappes informatiques hautes performances
• Infrastructure logicielle de bioinformatique avancée

Talent scientifique et technique spécialisé

Catégorie des employés	Nombre
Total des employés (Q4 2023)	129
Chercheurs de doctorat	37
Biologistes informatiques	22

Portefeuille de propriété intellectuelle

Détails de brevet à partir de 2024:

• Brevets totaux: 15
• Demandes de brevet en instance: 8
• Zones de brevet: technologie de séquençage, algorithmes d'analyse des données

Installations avancées de laboratoire et de recherche

Métrique de l'installation	Spécification
Espace de laboratoire total	6 500 pieds carrés
Investissement de recherche et développement (2023)	41,2 millions de dollars
Instruments de séquençage génomique	7 plateformes actives

Singular Genomics Systems, Inc. (OMIC) - Modèle d'entreprise: propositions de valeur

Technologies de séquençage génomique de haute précision

La génomique singulière propose la plate-forme de séquençage G4 avec les spécifications suivantes:

Métrique de performance	Spécification
Déborder	Jusqu'à 1,2 To par course
Temps d'exécution	26-48 heures
Longueur de lecture	Jusqu'à 2x300 paires de bases

Analyse génomique rentable et rapide

Structure de tarification pour le séquençage génomique:

Type de service	Coût par génome
Séquençage du génome entier	$1,200-$1,500
Séquençage ciblé	$500-$800

Solutions de pointe pour la médecine personnalisée

• Panneau en oncologie avec plus de 500 gènes liés au cancer
• Plateforme de diagnostic de maladies rares
• Capacités de test de pharmacogénomique

Outils de recherche avancés pour la découverte scientifique

Plateformes de recherche clés:

Plateforme de recherche	Application
Séquençage spatial de feu	Transcriptomique spatiale
Préparation de la bibliothèque de séquençage PIP	Bibliothèques génomiques à haute complexité

Plateformes innovantes pour la recherche génétique et le diagnostic

• Potentiel du marché clinique: 25,5 milliards de dollars d'ici 2026
• Flux de travail diagnostiques produits par la FDA
• Processus de laboratoire certifiés Clia et CAP

Singular Genomics Systems, Inc. (OMIC) - Modèle d'entreprise: relations clients

Équipes de vente directe et de support technique

Depuis le quatrième trimestre 2023, la génomique singulière a signalé 47 employés au total, avec environ 15 à 20% dédiés aux fonctions de vente directe et de support technique.

Canal de support client	Méthode de contact	Temps de réponse
Équipe de vente directe	Téléphone: (858) 225-2530	24-48 heures
Support technique	Courriel: support@singulargenomics.com	48-72 heures

Service client en ligne et documentation technique

La société maintient un portail d'assistance en ligne complet avec une documentation technique téléchargeable et des guides utilisateur.

• Documentation technique disponible au format PDF
• Base de connaissances en ligne avec plus de 150 articles techniques
• Manuels logiciels téléchargeables

Conseil personnalisé pour la recherche et les applications cliniques

La génomique singulière offre des services de conseil spécialisés pour la recherche génomique et les applications cliniques.

Type de service de conseil	Segment cible	Coût estimé
Consultation de recherche	Institutions universitaires	2 500 $ - 5 000 $ par projet
Soutien à l'application clinique	Fournisseurs de soins de santé	3 500 $ - 7 500 $ par engagement

Prise en charge de la formation et de la mise en œuvre des utilisateurs

L'entreprise propose des programmes de formation complets pour les utilisateurs de plate-forme.

• Sessions de formation en ligne de webinaire en ligne
• Ateliers de mise en œuvre sur place
• Packages de formation personnalisés pour les grandes institutions de recherche

Conférences scientifiques régulières et événements d'engagement

La génomique singulière participe à des conférences scientifiques clés pour s'engager avec des clients potentiels.

Type de conférence	Fréquence	Participation annuelle estimée
Conférence de recherche en génomique	Trimestriel	4-6 conférences par an
Symposium de diagnostic clinique	Bi-annuellement	2-3 événements par an

Singular Genomics Systems, Inc. (Omic) - Modèle d'entreprise: canaux

Force de vente directe ciblant les institutions de recherche

Depuis le quatrième trimestre 2023, la génomique singulière maintient une équipe de vente directe de 17 représentants spécialisés des ventes scientifiques ciblant les institutions de recherche.

Type de canal de vente	Nombre de représentants	Segment du marché cible
Ventes de recherche directes	17	Académique & Institutions de recherche

Plateforme de commerce électronique en ligne

La génomique singulière exploite une plate-forme de commande numérique avec un volume de transactions en ligne de 3,2 millions de dollars pour 2023.

Conférences scientifiques et salons commerciaux

Type de conférence	Participation annuelle	Coût moyen de l'événement
Conférences génomiques majeures	8-10 conférences	125 000 $ par événement

Marketing numérique et publications scientifiques

• Budget de marketing numérique: 1,4 million de dollars en 2023
• Investissements de publication scientifique: 350 000 $ par an
• Dépenses publicitaires numériques ciblées: 620 000 $

Partenariats avec les distributeurs et les revendeurs

Type de partenaire	Nombre de partenaires	Revenus annuels des partenariats
Distributeurs d'équipements scientifiques	12	4,7 millions de dollars

Singular Genomics Systems, Inc. (OMIC) - Modèle d'entreprise: segments de clientèle

Laboratoires de recherche universitaire

Depuis le quatrième trimestre 2023, la génomique singulière cible environ 2 500 laboratoires de recherche universitaire spécialisés dans le monde entier dans la recherche génomique.

Domaine de recherche	Nombre de laboratoires	Pénétration estimée du marché
Génomique	1,200	48%
Biologie moléculaire	850	34%
Recherche génétique	450	18%

Sociétés pharmaceutiques et biotechnologiques

En 2023, la génomique singulière dessert 127 sociétés pharmaceutiques et biotechnologiques.

• Top 20 sociétés pharmaceutiques: 18 clients directs
• Entreprises biotechnologiques de niveau intermédiaire: 62 clients
• Startups biotechnologiques émergentes: 47 clients

Centres de diagnostic clinique

En 2024, la génomique singulière a des partenariats avec 93 centres de diagnostic clinique à travers l'Amérique du Nord et l'Europe.

Région	Nombre de centres de diagnostic	Tests génomiques annuels
Amérique du Nord	62	1,240,000
Europe	31	620,000

Chercheurs en médecine de précision

En 2023, la génomique singulière a soutenu 215 équipes de recherche en médecine de précision dans le monde.

• Recherche contre le cancer: 85 équipes
• Troubles génétiques rares: 62 équipes
• Développement du traitement personnalisé: 68 équipes

Développeurs de technologies génomiques

En 2024, la génomique singulière collabore avec 43 organisations de développement de technologie génomique.

Focus technologique	Nombre d'organisations	Type de collaboration
Technologies de séquençage	22	Partenariat direct
Bioinformatique	12	Intégration technologique
Génomique informatique	9	Collaboration de recherche

Singular Genomics Systems, Inc. (Omic) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Singular Genomics Systems, Inc. a déclaré des frais de recherche et de développement totaux de 54,7 millions de dollars.

Catégorie de dépenses	Montant (millions de dollars)
Frais de personnel	28.3
Équipement de laboratoire	12.5
Matériaux consommables	8.2
Collaborations de recherche externe	5.7

Coûts de fabrication et de production

Les dépenses de fabrication de la société pour 2023 ont totalisé environ 22,1 millions de dollars.

• Coût de production du système de séquençage G4: 12,6 millions de dollars
• Procurement des matières premières: 6,5 millions de dollars
• Contrôle de la qualité et tests: 3,0 millions de dollars

Investissements de vente et de marketing

La génomique singulière a alloué 18,3 millions de dollars aux efforts de vente et de marketing en 2023.

Canal de marketing	Dépenses (millions de dollars)
Marketing numérique	5.7
Parrainages de conférence scientifique	4.2
Compensation de l'équipe de vente	8.4

Frais généraux administratifs

Les dépenses administratives pour 2023 ont été déclarées à 16,9 millions de dollars.

• Salaires des cadres et de la gestion: 7,6 millions de dollars
• Coûts juridiques et de conformité: 4,3 millions de dollars
• Infrastructure d'entreprise: 5,0 millions de dollars

Maintenance de la propriété intellectuelle

La société a dépensé 3,5 millions de dollars pour la maintenance de la propriété intellectuelle en 2023.

Catégorie de dépenses IP	Montant (millions de dollars)
Dépôt de brevet et poursuite	2.1
Services juridiques IP	1.4

Singular Genomics Systems, Inc. (OMIC) - Modèle d'entreprise: Strots de revenus

Vente de plateformes de séquençage génomique

Au quatrième trimestre 2023, la génomique singulière a déclaré un chiffre d'affaires de la plate-forme de 3,2 millions de dollars. La plate-forme de séquençage G4 était au prix d'environ 350 000 $ par unité.

Modèle de plate-forme	Prix ​​moyen	Ventes annuelles estimées
Système de séquençage G4	$350,000	9-12 unités par an

Consommables et ventes de réactifs

Les revenus consommables pour 2023 étaient de 5,7 millions de dollars, ce qui représente une source de revenus récurrente clé.

• Prix ​​du kit de réactif de séquençage: 5 000 $ - 7 500 $ par course
• Consommables annuels moyens par plate-forme: 150 000 $ - 200 000 $

Contrats de service et support technique

Les revenus annuels du contrat de soutien technique et du contrat de service ont totalisé 1,8 million de dollars en 2023.

Type de service	Coût annuel	Couverture contractuelle
Support standard	$25,000-$35,000	Mises à jour de base de la maintenance et des logiciels
Support premium	$50,000-$75,000	Assistance technique 24/7, réparations prioritaires

Licence des technologies propriétaires

Les revenus de licence en 2023 étaient de 2,1 millions de dollars des accords de transfert de technologie.

Accords de collaboration de recherche

Les accords de collaboration de recherche ont généré 4,5 millions de dollars de revenus en 2023.

Type de collaboration	Valeur de l'accord moyen	Nombre d'accords
Partenariats académiques	$250,000-$500,000	6-8 par an
Collaborations pharmaceutiques	1 à 3 millions de dollars	2-3 par an

Singular Genomics Systems, Inc. (OMIC) - Canvas Business Model: Value Propositions

You're looking at the core value Singular Genomics Systems, Inc. is delivering to researchers now that the G4X Spatial Sequencer is coming to market after its private acquisition by Deerfield Management in early 2025. The value propositions are centered on overcoming the historical bottlenecks of speed, scale, and multi-modality in genomics.

High-throughput spatial multiomics with the G4X platform

The G4X Spatial Sequencer is the main draw here, designed to handle massive spatial biology studies. This isn't just incremental improvement; it's about scale for clinical cohort work. For instance, data presented at AGBT in February 2025 showed the G4X could generate 3D multi-omic reconstructions from 10 serial kidney cancer FFPE sections, analyzing over 6.2 million cells and 438 million transcripts-all from a single G4X flow cell. That level of data density from one run directly translates to lower costs and faster insights for large-scale translational studies.

Dual-purpose instrument for both NGS and tissue-based spatial sequencing

This platform is engineered to be a true workhorse, not a single-use device. The G4X is positioned as the industry's first dual-purpose instrument, meaning it handles both traditional Next-Generation Sequencing (NGS) applications and the newer, complex tissue-based spatial sequencing. This flexibility helps labs maximize their capital expenditure. The platform is designed to support up to 128 samples per run for spatial applications, which is a significant jump in capacity for high-volume users.

Fast, accurate, and flexible benchtop genomic sequencing (G4 platform)

The established G4 Sequencing Platform still provides the foundation for high-quality, rapid NGS, which is crucial for labs needing speed without moving to massive, dedicated machines. The G4 chemistry delivers high quality, with data showing >85% of bases at or above a quality score of Q30, and in some 2025 reports, the average was cited as above 90% of bases at or above Q30. You can see the core specs that define this value:

Metric	G4 - F2 (Max)	G4 - F3 (Max)
Maximum Output per Run (Gb)	200.00	400.00
Run Time Range (Hours)	11 to 19	11 to 24
Bases $\ge$ Q30 Quality	>85%	>85%

The G4 was designed to sequence up to four human genomes in just 16-19 hours, which was up to three times more data output per hour than contemporary benchtop instruments at its launch.

Single-cell precision analysis of complex tumor-immune interactions

The G4X's multiomics capability is where it really shines for oncology and immunology research, allowing you to map multiple data types-RNA, protein, and morphology-in their original spatial context. This is key for understanding the tumor microenvironment. The platform has demonstrated the ability to perform high-sensitivity and specificity analysis on complex samples like FFPE tissues. The system supports advanced applications like:

• 500-Plex Spatial Transcriptomics for barcode-free RNA detection.
• 18 Plex Spatial Proteomics for mapping protein expression.
• Accurate T- and B-cell receptor sequencing in FFPE samples using Direct-Seq technology.

This integrated view helps researchers see how millions of cells interact spatially, which is vital for biomarker discovery.

Reproducibility and cost-efficiency for large-scale spatial studies

For any large study, especially those moving toward translational settings, reproducibility is non-negotiable. Early access sites have specifically cited the reproducibility and cost-efficiency of the G4X as major benefits, enabling the scaling of 3D spatial analyses in larger retrospective cohorts. While the company's TTM revenue as of November 2025 was reported at $2.66 Million USD, the value proposition is focused on the customer's cost reduction through higher throughput and lower turnaround times, which drives a higher return-of-investment for core facilities. The ability to generate this high-dimensional data reproducibly across serial FFPE sections is what unlocks those large-scale 3D molecular studies.

Singular Genomics Systems, Inc. (OMIC) - Canvas Business Model: Customer Relationships

You're looking at how Singular Genomics Systems, Inc. manages its relationships with its high-value scientific customers, especially as they transition to the new G4X Spatial Sequencer. Honestly, for capital equipment in this space, the relationship is everything; it's not a one-time transaction.

Dedicated field application specialists and technical support

The relationship hinges on keeping the installed base running smoothly and helping them get the most out of the technology. For the existing G4 fleet, system uptime averaged a solid 95% during Q2 2024. This operational reliability is key to securing future consumable revenue, which is the recurring part of the model. The annualized consumables pull-through for the installed G4 base was approximately $60,000 per system in Q2 2024, which was about double the pull-through seen in Q1 2024, showing increasing customer engagement with the platform's workflow. You can reach out to the support team via the dedicated channel at care@singulargenomics.com.

Here's a quick look at the G4 installed base utilization metrics from the last reported quarter:

Metric	Value (as of Q2 2024)	Context
System Uptime Average	95%	Fleet health indicator
Annualized Consumables Pull-Through	$60,000	Per system, Q2 2024
Q2 Consumables Pull-Through vs Q1 2024	Double	Indicates growing usage

Early Access Programs for G4X to build advocacy and feedback

For the G4X Spatial Sequencer, the relationship strategy is centered on building strong early advocates before the broader commercial launch planned for around Q2 2025. The G4X Early Access Program was underway as of February 2025 at key institutions like Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center. Singular planned to expand this program to a few more sites in Q2 2025. These early adopters are crucial; they generate the initial high-impact data and testimonials that drive later commercial demand. The initial early access units were designed to be revenue-producing, though with appropriately set expectations regarding support levels.

• Initial EAP sites included Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center.
• Expansion of the EAP was planned for Q2 2025.
• The program aims to generate technical publications and Key Opinion Leader (KOL) testimonials.

Direct sales and service model for high-value capital equipment

The core of the capital equipment relationship is a direct sales approach, which is necessary for high-touch, high-value instruments like the G4 and the upcoming G4X. The G4 system shipments in Q1 2024 showed this segmentation: four units went to academic core or medical center labs, and two went to commercial labs, bringing the total G4 shipments to 30 as of March 31, 2024. This direct interaction allows Singular Genomics Systems, Inc. to manage complex installations and service agreements upfront. The model relies on driving initial adoption, followed by recurring revenue from consumables sales, as seen by the Q3 2024 revenue of $0.4 million, primarily from consumables.

Technology Access Services for initial data generation projects

To bridge the gap before G4X instrument shipments began in June 2025, the company offered Technology Access Services. Researchers could use these services to start generating multiomic data immediately. This service acts as a low-friction entry point, allowing potential customers to validate the platform's value proposition with their own samples without a capital commitment. Data from two initial Technology Access Partner projects were showcased at the AACR 2024 conference. This service funnel was cited as exceeding 50 opportunities, indicating strong inbound interest for the G4X capabilities.

The focus on services helps de-risk the capital purchase for the customer. It's a smart way to build a pipeline; you let them see the results first.

Singular Genomics Systems, Inc. (OMIC) - Canvas Business Model: Channels

You're looking at the commercial channels for Singular Genomics Systems, Inc. after its transition to a private entity under Deerfield Management in February 2025. The focus shifts from public market scrutiny to driving adoption of the G4X™ Spatial Sequencer, which had its full commercial release expected around the second quarter of 2025. The company's overall trailing twelve months (TTM) revenue as of December 2025 stood at $2.66 Million USD, which gives you the scale of the current commercial engine.

Direct Sales Force (focused on North America and key markets)

The initial commercialization strategy centered on a direct sales and marketing organization within the United States for the G4 Sequencing Platform. Post-acquisition, this direct model is the most likely path for driving adoption of the newer, high-value G4X system, especially in North America, which remains the primary focus. While the exact size of the sales team as of late 2025 isn't public, the company previously reported having 220 total employees, which provided the foundation for R&D, operations, and commercial efforts.

The plan, even pre-acquisition, included future expansion into the European Union, United Kingdom, Asia Pacific, and Japan, likely through a mix of direct sales and established distribution networks as scale permits. Right now, though, the channel investment is definitely concentrated on securing key accounts in the US.

Scientific conferences and showcases (e.g., AGBT, Spatial Summit)

Scientific engagement is a critical channel for a life sciences tool company, serving as both a marketing platform and a direct feedback loop. Singular Genomics Systems, Inc. has historically used major industry events to showcase platform performance. For instance, milestones for the G4X were highlighted through presentations at events like AGBT and SITC, which validates the technology to key opinion leaders.

These showcases are where the company converts scientific interest into pipeline opportunities. The goal is to get the G4X in front of researchers working on high-throughput spatial multiomics, a segment the global single-cell omics market is projected to grow significantly in, with instruments holding nearly 60% of that market share.

Online presence for product information and technical support

The company maintains its presence at www.singulargenomics.com for product details, technical specifications, and investor relations information, though the latter is now private. This digital channel supports the direct sales force by providing accessible technical documentation and supporting existing customers. For a company whose Q3 2024 revenue was only $0.4 Million USD, a lean, high-touch digital support structure is necessary to manage the installed base and support early G4X users without ballooning Selling, General and Administrative (SG&A) expenses.

Technology Access Services for pre-instrument adoption

This service acts as a crucial pre-sales channel, letting potential high-volume customers experience the G4X platform without an upfront capital commitment. Interest in G4X was being built via the Spatial Technology Access Services funnel, which is designed to generate data and build case studies before a full instrument sale. This model is tied to the reagent rental aspect that pressured gross margins in 2024, meaning revenue recognition is likely spread out over time, even for service-based access.

The early access program saw the shipment of the first G4X Early Access instrument in Q3 2024, demonstrating this channel was active and generating data, such as processing 6.2 million cells from a single G4X flow cell in one example. This service is the bridge between initial interest and capital equipment purchase.

Here's a quick look at the commercial context surrounding these channels as of late 2025:

Metric	Value as of Late 2025 Context	Reference Period/Context
TTM Revenue	$2.66 Million USD	As of December 2025
G4 Systems Shipped (Example)	2 units	Q3 2024 (Pre-full G4X launch)
G4X Early Access Instruments Shipped	1 unit	Q3 2024
Acquisition Price Per Share	$20.00 in cash	Completed February 21, 2025
Total Employees (Historical Baseline)	220	General Company Size

The channel strategy is clearly focused on demonstrating high-throughput spatial sequencing capability through direct engagement at key scientific venues and via the Technology Access Services funnel to drive future instrument placements. The modest TTM revenue of $2.66 Million USD shows the commercial ramp is still in its early stages, even with the G4X launch underway.

• Focus on North America for initial direct sales penetration.
• Leverage high-impact scientific conferences like AGBT for platform validation.
• Utilize Technology Access Services to de-risk G4X adoption for core labs.
• Future channel expansion planned for EU, UK, Asia Pacific, and Japan.

Singular Genomics Systems, Inc. (OMIC) - Canvas Business Model: Customer Segments

You're looking at the customer landscape for Singular Genomics Systems, Inc. (OMIC) as they push their integrated sequencing and spatial multiomics platforms. The customer base is clearly segmented across the research and translational continuum, which dictates how they recognize revenue-often through initial system placements followed by recurring consumables sales, or through reagent rental models.

As of the latest reported figures (Q3 2024), the commercial traction, which reflects early customer adoption, involved shipping two G4 systems and the first G4X Early Access instrument in that quarter. The company has explicitly noted a deep services funnel across the key segments you mentioned, suggesting active engagement with all of them.

Here's a breakdown of the primary customer segments Singular Genomics Systems, Inc. (OMIC) targets with its G4 Sequencing Platform and PX Integrated Solution:

• Academic research institutions and core labs
• Biopharmaceutical companies (biopharma) for drug discovery
• Contract Research Organizations (CROs) for high-volume studies
• Translational and clinical trial settings for biomarker identification

The G4X spatial sequencer is specifically positioned to address throughput limitations in these segments. The Technology Access Partner (TAP) projects, such as those with Dana-Farber and the Broad Institute, give us concrete examples of early adopters within the academic research space.

The financial reality of these early-stage customer engagements is reflected in the Q3 2024 revenue, which was only $0.4 million, driven primarily by consumables sales, indicating that the installed base is still small and revenue recognition from capital equipment sales is not yet dominant.

The following table maps the core platforms to the customer segments and their primary application focus, using the latest available product deployment data as a proxy for current segment engagement:

Customer Segment	Primary Platform Focus	Latest Deployment Metric (Q3 2024)	Stated Application Areas
Academic research institutions and core labs	G4 Sequencing Platform, G4X Spatial Sequencer	Expansion of TAP projects (e.g., Broad Institute)	Basic biology, oncology, immunology, neurology, genetic diseases
Biopharmaceutical companies (biopharma)	PX Integrated Solution, G4X Spatial Sequencer	Deep services funnel engagement	Drug discovery, oncology, spatial analysis, proteomics
Contract Research Organizations (CROs)	G4X Spatial Sequencer (for high-throughput)	Deep services funnel engagement	High-volume studies, translational research
Translational and clinical trial settings	PX Integrated Solution	Focus on biomarker identification	Oncology, infectious diseases, human microbiome

For the academic segment, the installed base of G4 systems grew to 30 commercial systems by Q1 2024, showing initial penetration before the broader G4X commercial launch targeted around Q2 2025. The revenue model appears heavily weighted toward consumables pull-through, as evidenced by the Q3 2024 revenue of $0.41 million being primarily from consumables.

Finance: draft 13-week cash view by Friday.

Singular Genomics Systems, Inc. (OMIC) - Canvas Business Model: Cost Structure

You're looking at the cost side of Singular Genomics Systems, Inc.'s (OMIC) operations as they push the G4X spatial sequencer toward broader commercialization around Q2 2025. The cost structure is heavily weighted toward development and early-stage commercialization pressures.

High R&D expenses for G4X and Direct-Seq technology

The development and launch of the G4X spatial sequencer, which supports Direct-Seq technology, drives substantial operating costs. While explicit R&D figures aren't broken out separately in the latest reports, the overall operating expense base reflects this investment. Management implemented cost actions in March 2024 to lower the burn rate, but development costs remain significant.

• Q3 2024 Operating Expenses totaled $17.8 million.
• Q1 2024 cash burn was approximately $23.2 million.
• The company is focused on shifting resources to G4X development and commercialization.

Cost of Goods Sold (COGS) for instruments and consumables

The cost structure for revenue generation is challenged by aggressive pricing strategies for instruments and the nature of early-stage service/rental models. The G4 instrument price was reduced to $295,000 from an initial $350,000. The G4X system itself is listed at $495,000. Reagent costs for sequencing on the G4X start around $240 per lane for F3 100 Cycle paired reads.

Here's a look at the pricing structure for G4X customization and sequencing, which directly impacts the variable cost component of revenue:

G4X Customization/Assay	Order Fee (1 FC)	Price / FC after
50-Gene Add-On Craft Panel	$2,500	$250
150-Gene Add-On Craft Panel	$5,000	$500
350-Gene De-Novo Craft Panel	$10,000	$1,000

Next Generation Sequencing on G4X (F3 Paired Reads)	$ / FC	$ / Lane
100 Cycle (100M / Lane)	$920	$240
300 Cycle (100M / Lane)	$1,200	$300

Sales, General, and Administrative (SG&A) expenses

SG&A is bundled within the reported Operating Expenses, which management actively worked to reduce. Following cost actions, operating expenses fell year-over-year in Q3 2024. The company guided for operating expenses to be 10-15% lower sequentially in Q2 2024 compared to Q1 2024.

• Q3 2024 Operating Expenses were $17.8 million, down from $24.5 million year-over-year.
• Operating expenses in Q4 2023 totaled $24.8 million.
• Cost-saving initiatives, including a 20% workforce reduction, aimed for approximately $20 million in annualized OpEx savings.

Negative gross profit due to early-stage discounts and rental models

Singular Genomics Systems, Inc. reported negative gross profit in recent quarters, a direct consequence of its commercial strategy during the G4 and G4X transition. This pressure comes from providing discounts on capital purchases and utilizing reagent rental/evaluation models instead of upfront sales.

• Q3 2024 Gross Profit was negative $0.3 million.
• Q1 2024 gross profit was negative, attributed to discounts, reagent rental/non-capital models, and higher support costs.
• In Q4 2023, gross profit was negative $0.5 million, also due to discounts and higher installation/support costs.

Significant cash burn (Q1 2024 was around $23.2 million)

The high operating expenses and negative gross profit resulted in a significant cash burn rate in early 2024, which management took steps to mitigate to extend the cash runway. The company ended Q3 2024 with $113.8 million in cash and investments.

• Q1 2024 cash burn was approximately $23.2 million.
• Management guided for lower cash burn in Q2 2024 as cost savings took effect.
• The company expected its cash runway to extend into late 2026 following cost reduction measures.

Singular Genomics Systems, Inc. (OMIC) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Singular Genomics Systems, Inc. (OMIC) as of late 2025, post-acquisition by Deerfield Management. The model is clearly leaning toward a razor-and-blades approach, even if the initial numbers reflect a very early commercial stage.

The overall financial picture, based on the Trailing Twelve Months (TTM) ending around the time of the acquisition and subsequent period, shows a small revenue base, which is typical for a company transitioning from R&D to commercial scale with new platforms like the G4 and the newly launched G4X.

Trailing Twelve Months (TTM) Revenue as of Late 2024/Early 2025 Context:

Metric	Amount
TTM Revenue (as of late 2024/early 2025)	$2.66 Million USD

The revenue streams are segmented by the core product strategy, which relies on getting the instrument into the lab first to secure future consumable sales. Here's how the streams break down:

• Sales of G4 and G4X Sequencing Instruments (capital purchases)
• Recurring revenue from Consumables and Reagents (pull-through)
• Instrument service contracts and support fees
• Technology Access Services (spatial services)

Sales of G4 and G4X Sequencing Instruments (Capital Purchases):

Instrument sales represent the initial, lumpy revenue component. You see this in the quarterly reports leading up to the privatization. For instance, in the second quarter of 2024, revenue included $0.3 million from one capital purchase instrument placement, alongside 2 G4 systems shipped that quarter. By the third quarter of 2024, the company shipped two G4 systems and the first G4X Early Access instrument, though instrument revenue is expected to be recognized over time as consumables are purchased. The commercial launch of the G4X was targeted for around the end of the second quarter of 2025, meaning late 2025 revenue should start reflecting initial G4X capital sales, though the focus is shifting to services and pull-through.

Recurring Revenue from Consumables and Reagents (Pull-Through):

This is the intended long-term engine. The strategy is explicitly to drive ongoing revenue by having customers purchase proprietary consumables after installing the instrument base. Consumables were the primary revenue driver in the early commercial phase. In the first quarter of 2024, revenue of $0.4 million consisted primarily of consumables sales and one instrument capital purchase. Similarly, in the third quarter of 2024, revenue of $0.4 million was reported, driven primarily by consumables sales. The annualized consumables pull-through per G4 system was noted to be roughly $60,000 in the second quarter of 2024, which was about double the rate seen in the first quarter. That recurring number is what the private ownership will be keenly watching.

Instrument Service Contracts and Support Fees:

Service contracts and support fees are a standard component for complex capital equipment. While specific dollar amounts for this stream aren't broken out separately in the public filings, these costs negatively impact gross profit when systems are placed under reagent rental or initial support is high. Post-acquisition, you can expect a more formalized structure for service contracts, likely bundled or offered as a distinct recurring fee stream to stabilize margins, especially as the installed base grows.

Technology Access Services (Spatial Services):

This represents the early monetization of the G4X platform before full commercial launch. The company launched a Spatial Sequencing Technology Access Services program in the second quarter of 2024. This service stream allows early adopters to use the G4X capabilities in-house or via a service model, generating revenue while gathering critical feedback. The interest in the G4X services funnel exceeded 50 opportunities by mid-2024, indicating a strong pipeline for this revenue category as the G4X became available.